Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung

An active drug combination with major nonhematologic toxicity

D. C. Ihde, M. H. Cohen, P. A. Bunn, A. M. Bernath, L. E. Broder, J. D. Minna

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)155-157
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number1
StatePublished - 1978

Fingerprint

Bleomycin
Drug Combinations
Streptozocin
Methotrexate
Squamous Cell Carcinoma
Semustine
Lomustine
Lung
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung : An active drug combination with major nonhematologic toxicity. / Ihde, D. C.; Cohen, M. H.; Bunn, P. A.; Bernath, A. M.; Broder, L. E.; Minna, J. D.

In: Cancer Treatment Reports, Vol. 62, No. 1, 1978, p. 155-157.

Research output: Contribution to journalArticle

@article{8ba307fbc354484995d86d4f8a26ab72,
title = "Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: An active drug combination with major nonhematologic toxicity",
abstract = "Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13{\%} and 25{\%} respectively in epidermoid lung cancer. Given together, they induced regressions in 53{\%} of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.",
author = "Ihde, {D. C.} and Cohen, {M. H.} and Bunn, {P. A.} and Bernath, {A. M.} and Broder, {L. E.} and Minna, {J. D.}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "155--157",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung

T2 - An active drug combination with major nonhematologic toxicity

AU - Ihde, D. C.

AU - Cohen, M. H.

AU - Bunn, P. A.

AU - Bernath, A. M.

AU - Broder, L. E.

AU - Minna, J. D.

PY - 1978

Y1 - 1978

N2 - Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

AB - Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

UR - http://www.scopus.com/inward/record.url?scp=0017853567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017853567&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 155

EP - 157

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -